Breast cancer patients with node-negative disease and ductal carcinoma in situ (DCIS) should routinely have a secondary pathology review, according to a retrospective Canadian study.
The authors found that 81 of 405 (20%) such patients had changes made to their pathology report after a second look. Ultimately, treatment was modified for 25 patients (6%).
Žádné komentáře:
Okomentovat
Poznámka: Komentáře mohou přidávat pouze členové tohoto blogu.